Expert Interviews Medical World News Podcasts Case Based Roundtable Series Case of the Quarter EyeView Grand Rounds Insights Rapid Readout Viewpoints What’s Your WhEYE?

Conference Coverage Conference Listing

Events

Digital Edition Europe Ophthalmology Times Modern Retina Supplements and Featured Publications

CME Partners Subscribe

Cataract Therapeutics

Interventional Glaucoma Interventional Glaucoma Interventional Glaucoma Interventional Glaucoma

OCT

Ocular Allergy

Ocular Surface Disease

Practice Management Practice Management

Presbyopia

Ptosis

Refractive Refractive

Understanding Antibiotic Resistance

Workplace

Spotlight -

Retina

Cataract Therapeutics

Interventional Glaucoma Interventional Glaucoma Interventional Glaucoma Interventional Glaucoma

OCT

Ocular Allergy

Ocular Surface Disease

Practice Management Practice Management

Presbyopia

Ptosis

Refractive Refractive

Understanding Antibiotic Resistance

Workplace

Advanced Therapies for Retinal Vascular Diseases: Enhancing Durability and Reducing Treatment Burden : Episode 1

Opinion

Video

November 15, 2024

Case 1: Treatment-Naïve Neovascular Age-Related Macular Degeneration

Author(s):

Lisa J. Faia, MD ,David R. Lally, MD

In the first case, David Lally, MD presents a patient case of age-related macular degeneration (AMD) highlighting the superior durability of newer treatments.

Now Viewing

EP: 1.Case 1: Treatment-Naïve Neovascular Age-Related Macular Degeneration

EP: 2.First Line Treatment Decisions for Age-Related Macular Degeneration

EP: 3.Case 2: Diabetic Macular Edema With Severe Vision Loss

EP: 4.MOA and Improved Outcomes: Gaps in Measuring Real-World Results

EP: 5.Case 3: Persistently Active Central Retinal Vein Occlusion

EP: 6.Safety of Advanced Therapies in Clinical Trials vs Real World Experience

EP: 7.Case 4: Neovascular Age-Related Macular Degeneration with Serious Pigment Epithelial Detachment

EP: 8.Final Thoughts on Case Presentations and Advanced Therapies

EP: 9.Aurion Biotech announces topline results from Phase 1/2 trial of AURN001 for corneal edema

Related Content

January 3rd 2025

European Medicines Agency to assess semaglutide for link to NAION

December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

December 27th 2024

Alert: Alcon voluntarily recalls Systane Ultra PF lot due to potential fungal contamination

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together

November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

December 4th 2024

Foundation Fighting Blindness joins University of Colorado Anschutz Medical Campus and leading institutions receive funding to fast track whole eye transplantation program

November 26th 2024

Researchers find new model of neuronal circuit provides insight on eye movement

Do Not Sell My Personal Information

Job Board

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777